Cancer Detection Recovered Following Pandemic Disruptions
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 22, 2024 -- Overall, cancer detection in the United States recovered meaningfully in 2021 following substantial disruptions in 2020, according to a study published online Oct. 14 in JAMA Network Open.
Uriel Kim, M.D., Ph.D., from the Cedars-Sinai Medical Center in Los Angeles, and colleagues evaluated the disruption and potential recovery in cancer detection during the first (2020) and second (2021) years of the COVID-19 pandemic. The analysis included data on roughly 15.8 million patients with incident cancer (2000 through 2021) identified from the Surveillance, Epidemiology, and End Results Program.
The researchers found that the percentage difference between the expected and observed cancer incidence in 2020 was −8.6 percent, with no significant difference in 2021 (−0.2 percent). During 2020 to 2021, there was a cumulative deficit in observed versus expected cases of −127,931. Incidence rates remained substantially depressed from expected rates into 2021 for certain subgroups, including patients living in the most rural counties (−4.9 percent). The largest cumulative deficit in observed versus expected cases occurred for cancers in the lung and bronchus (−24,940 cases), prostate cancer (−14,104 cases), and melanoma (−10,274 cases).
"The findings suggest that cancer detection needs to recover further in future years to address patients whose cancer went undiagnosed because of the pandemic," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Further Support and Information on COVID-19
Read this next
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...
Random Forest AI Model Superior for Inpatient Mortality Prognostication in Cirrhosis
THURSDAY, July 24, 2025 -- For inpatients with cirrhosis, a machine learning (ML) model using random forest (RF) analysis is superior for prediction of inpatient mortality...
Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome
THURSDAY, July 24, 2025 -- The Prognostic Nutritional Index (PNI) and systemic oxidative stress (SOS) score are independently associated with poorer prognosis of low-risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.